Personalised Cancer Immunotherapy

The right treatment,
at the right moment.

Kairos Oncology is building a personalised mRNA cancer immunotherapy platform, applying AI-driven bioinformatics to design individualised treatments for patients with high unmet need.

What we do

A platform for personalised cancer treatment

Every patient's cancer is genetically unique. We use computational genomics and machine learning to identify each patient's tumour-specific targets, then design an individualised mRNA immunotherapy matched to their cancer.

We are preparing a multi-indication Phase 1 clinical trial in Australia.

AI-driven neoantigen selection
Proprietary computational pipeline analysing patient tumour genomics to identify and rank optimal immunotherapy targets for each individual.
Personalised mRNA immunotherapy
Individually designed treatments tailored to each patient's unique tumour profile, manufactured to GMP standard and administered under clinical trial protocols.
Cancer-agnostic platform
The same platform applies across solid tumour types. Adding a new cancer indication changes the target selection, not the underlying technology.
Clinical-stage
Preparing for a registered clinical trial under Australian TGA oversight with full ICH-GCP compliance, generating data recognised by international regulatory authorities.
Get in touch

We welcome enquiries

From potential clinical collaborators, manufacturing partners, scientific advisors, and investors.

Enquiries
hello@kairosoncology.com
Location
Sydney, Australia